Brief: Ose Immunotherapeutics Provides Positive Long Term Memory Responses With Covepit, Its T Lymphocyte Multi-Target Anti-Covid Vaccine
16/03/2022 17:02
March 16 (Reuters) - OSE Immunotherapeutics SA OSE.PA :
* OSE IMMUNOTHERAPEUTICS PROVIDES POSITIVE LONG TERM MEMORY
RESPONSES WITH COVEPIT, ITS T LYMPHOCYTE MULTI-TARGET ANTI-COVID
VACCINE
* OSE IMMUNOTHERAPEUTICS SA - VACCINE REMAINS INDEPENDENT OF
MUTATIONS IDENTIFIED IN CURRENT AND EMERGING VARIANTS
* OSE IMMUNOTHERAPEUTICS - POSITIVE LONG TERM IMMUNOLOGICAL
RESULTS AT 6 MONTHS IN HEALTHY VOLUNTEERS WITH STRONG T CELL
MEMORY RESPONSES AGAINST VIRUS PROTEINS
Source text for Eikon: urn:newsml:reuters.com:*:nGNX1c05Td
Further company coverage: OSE.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ose Immunotherapeutics SA
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Brief: OSE Immunotherapeutics SA Appoints Thomas Gidoin As Deputy CEO
Brief: Ose Immunotherapeutics Will Pause Development Of OSE‑230
Brief: OSE Immunotherapeutics Gets Second Positive IDMC Nod For Phase 3 Lung Cancer Trial
Brief: OSE Immunotherapeutics Announces Appointment Of Marc Le Bozec As Interim CEO